A Study of Sovilnesib in Subjects with Ovarian Cancer

Study Number

3766923

Phase

Age Group

Adult

Principal Investigator

Purpose

This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).

Check your eligibility for this trial

Check now

Full Title

A phase 1b dose optimization study of sovilnesib (an oral KIF18A inhibitor) in subjects with advanced high grade serous ovarian cancer

ClinicalTrials.Gov ID

NCT06084416

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.